MX2009003730A - Purificacion de polisacaridos de streptococcus pneumoniae tipo 3. - Google Patents
Purificacion de polisacaridos de streptococcus pneumoniae tipo 3.Info
- Publication number
- MX2009003730A MX2009003730A MX2009003730A MX2009003730A MX2009003730A MX 2009003730 A MX2009003730 A MX 2009003730A MX 2009003730 A MX2009003730 A MX 2009003730A MX 2009003730 A MX2009003730 A MX 2009003730A MX 2009003730 A MX2009003730 A MX 2009003730A
- Authority
- MX
- Mexico
- Prior art keywords
- lysate
- methods
- precipitation
- cause
- aggregation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/831—Drug, bio-affecting and body treating compositions involving capsular polysaccharide of bacterium, e.g. polyribosyl ribitol phosphate
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Materials Engineering (AREA)
- Polymers & Plastics (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
- Compounds Of Unknown Constitution (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
La presente invención proporciona métodos mejorados para la reducción o separación de impurezas proteínicas de un complejo celular de lisado o concentrado de Streptococcus pneumoniae que comprende polisacáridos serotipo 3, que involucran las etapas en relación al calentamiento posterior a lisis o ajuste de pH. En algunos métodos, el lisado se calienta durante un tiempo y una temperatura suficientes para desnaturalizar proteínas presentes en el lisado y provocar su agregación y precipitación. En una modalidad, el lisado se calienta a por lo menos 60ºC durante por lo menos 30 minutos para provocar agregación y precipitación proteínicas, de manera más particular, entre aproximadamente 60ºC y aproximadamente 70ºC durante aproximadamente 30 y aproximadamente 50 minutos, e incluso de manera más particular a aproximadamente 65ºC durante aproximadamente 40 minutos. En otros métodos, el pH del lisado o concentrado se incrementa a por lo menos 8.0 para mejorar la susceptibilidad a, de manera más particular entre aproximadamente 8.0 y 8.4, e incluso de manera más particular aproximadamente 8.2. En métodos adicionales, se combinan las etapas de calentamiento y ajuste de pH para provocar agregación y precipitación proteínicas así como para mejorar la susceptibilidad a filtrados de los lisados o concentrados. En otros métodos, el pH del lisado o concentrado se disminuye a aproximadamente 3.0 a aproximadamente 5.0 para provocar agregación y precipitación proteínicas. Los métodos permiten la producción de lisados o concentrados que contienen polisacáridos serotipo 3 sustancialmente purificados.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85066506P | 2006-10-10 | 2006-10-10 | |
| PCT/US2007/080768 WO2008045852A2 (en) | 2006-10-10 | 2007-10-09 | Purification of streptococcus pneumoniae type 3 polysaccharides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2009003730A true MX2009003730A (es) | 2009-04-22 |
Family
ID=39156240
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009003730A MX2009003730A (es) | 2006-10-10 | 2007-10-09 | Purificacion de polisacaridos de streptococcus pneumoniae tipo 3. |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US7659090B2 (es) |
| JP (1) | JP5260531B2 (es) |
| KR (1) | KR101467002B1 (es) |
| CN (2) | CN101522906B (es) |
| AT (1) | ATE473289T1 (es) |
| AU (1) | AU2007307800C1 (es) |
| BR (2) | BR122019021950B8 (es) |
| CA (1) | CA2665169C (es) |
| CL (1) | CL2007002909A1 (es) |
| DE (1) | DE602007007642D1 (es) |
| DK (1) | DK2074221T3 (es) |
| ES (1) | ES2346929T3 (es) |
| HK (1) | HK1174836A1 (es) |
| IL (2) | IL197782A (es) |
| MX (1) | MX2009003730A (es) |
| PT (1) | PT2074221E (es) |
| RU (1) | RU2460539C2 (es) |
| WO (1) | WO2008045852A2 (es) |
| ZA (1) | ZA200902502B (es) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0822634D0 (en) | 2008-12-11 | 2009-01-21 | Novartis Ag | Meningitis vaccines |
| RU2524436C2 (ru) | 2008-12-18 | 2014-07-27 | УАЙТ ЭлЭлСи | Способ получения жидкой фракции, содержащей изолированные высокомолекулярные капсульные полисахариды streptococcus pneumoniae, и жидкая фракция, полученная таким способом |
| RU2511404C2 (ru) | 2008-12-18 | 2014-04-10 | УАЙТ ЭлЭлСи | Способ получения раствора, содержащего высокомолекулярные изолированные капсульные полисахариды streptococcus pneumoniae серотипа 19а (варианты) |
| RU2555757C2 (ru) | 2009-03-24 | 2015-07-10 | Новартис Аг | Комбинации менингококкового фактор н-связывающего белка и пневмококковых сахаридных конъюгатов |
| EP2411048B1 (en) | 2009-03-24 | 2020-05-06 | GlaxoSmithKline Biologicals SA | Adjuvanting meningococcal factor h binding protein |
| KR101450958B1 (ko) | 2009-04-30 | 2014-10-15 | 콜레이 파마시티컬 그룹, 인코포레이티드 | 폐렴구균 백신 및 그의 용도 |
| WO2011161653A1 (en) | 2010-06-25 | 2011-12-29 | Novartis Ag | Combinations of meningococcal factor h binding proteins |
| CN102094053B (zh) * | 2010-11-26 | 2013-01-16 | 兰州生物制品研究所有限责任公司 | 肺炎链球菌c多糖的纯化方法 |
| CA2828844C (en) | 2011-03-02 | 2020-07-14 | Novartis Ag | Combination vaccines with lower doses of antigen and/or adjuvant |
| BR112014016223A8 (pt) | 2011-12-29 | 2017-07-04 | Novartis Ag | combinações adjuvantes de proteínas de ligação de fator h meningocócico |
| US20150132339A1 (en) | 2012-03-07 | 2015-05-14 | Novartis Ag | Adjuvanted formulations of streptococcus pneumoniae antigens |
| JP2015509963A (ja) | 2012-03-08 | 2015-04-02 | ノバルティス アーゲー | Ｔｌｒ４アゴニストを含む混合ワクチン |
| AU2013311702A1 (en) | 2012-09-06 | 2015-02-19 | Novartis Ag | Combination vaccines with serogroup B meningococcus and D/T/P |
| BR112015005081B1 (pt) | 2012-09-07 | 2021-10-26 | Sk Bioscience Co., Ltd. | Método para produzir um polissacarídeo capsular tendo um sorotipo de pneumococo |
| JP2016502994A (ja) | 2012-12-18 | 2016-02-01 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | ジフテリア及び／又は破傷風から防御するためのコンジュゲート |
| MX371453B (es) | 2014-01-21 | 2020-01-29 | Pfizer | Polisacaridos capsulares de streptococcus pneumoniae y conjugados de los mismos. |
| US11160855B2 (en) | 2014-01-21 | 2021-11-02 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| AU2015208821B2 (en) | 2014-01-21 | 2017-11-02 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| CN105934251A (zh) | 2014-01-21 | 2016-09-07 | 辉瑞大药厂 | 肺炎链球菌荚膜多糖及其缀合物 |
| FI3244917T3 (fi) | 2015-01-15 | 2023-05-25 | Pfizer | Immunogeenisiä koostumuksia pneumokokkirokotteissa käytettäväksi |
| BR112017023437B1 (pt) | 2015-04-28 | 2022-03-22 | Biological E Limited | Métodos para o isolamento de polissacarídeo capsular de bactérias e composição imunogênica |
| IL297740A (en) | 2015-05-04 | 2022-12-01 | Pfizer | Protein-polysaccharide conjugates of group b streptococcus, methods for preparing the conjugates, immunogenic preparations containing conjugates and their uses |
| TWI756893B (zh) | 2015-07-21 | 2022-03-01 | 美商輝瑞股份有限公司 | 包含經共軛之莢膜糖抗原的致免疫性組成物、包含該致免疫性組成物之套組及彼等之用途 |
| CA3005524C (en) | 2015-11-20 | 2023-10-10 | Pfizer Inc. | Immunogenic compositions for use in pneumococcal vaccines |
| EP3493840B1 (en) | 2016-08-05 | 2022-08-24 | Sanofi Pasteur Inc. | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| MX2019001342A (es) | 2016-08-05 | 2019-07-04 | Sanofi Pasteur Inc | Composicion de conjugado de proteina-polisacarido de neumococo multivalente. |
| US10751402B2 (en) | 2016-11-09 | 2020-08-25 | Pfizer Inc. | Immunogenic compositions and uses thereof |
| US11951165B2 (en) | 2016-12-30 | 2024-04-09 | Vaxcyte, Inc. | Conjugated vaccine carrier proteins |
| KR20190103256A (ko) | 2016-12-30 | 2019-09-04 | 수트로박스, 인코포레이티드 | 비자연 아미노산을 갖는 폴리펩타이드-항원 접합체 |
| DK3570879T3 (da) | 2017-01-20 | 2022-04-11 | Pfizer | Immunogene sammensætninger til anvendelse i pneumokokvacciner |
| EP3576784A4 (en) | 2017-01-31 | 2020-11-11 | Merck Sharp & Dohme Corp. | PROCESS FOR THE PRODUCTION OF POLYSACCHARIDE PROTEIN CONJUGATES |
| JP2020514326A (ja) | 2017-02-24 | 2020-05-21 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | 肺炎連鎖球菌多糖−タンパク質コンジュゲートの免疫原性の増強 |
| US10702596B2 (en) | 2017-07-05 | 2020-07-07 | Inventprise, Llc | Polysaccharide purification for vaccine production using lytic enzymes, tangential flow filtration, and multimode chromatography |
| CA3068983A1 (en) | 2017-07-05 | 2019-01-10 | Inventprise, Llc | Polysaccharide purification for vaccine production using lytic enzymes, tangential flow filtration, and multimode chromatography |
| KR20200051005A (ko) | 2017-09-07 | 2020-05-12 | 머크 샤프 앤드 돔 코포레이션 | 폐렴구균 폴리사카라이드 및 면역원성 폴리사카라이드-담체 단백질 접합체에서의 그의 용도 |
| AU2018328035B2 (en) | 2017-09-07 | 2024-03-07 | Chitrananda Abeygunawardana | Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates |
| EP3720483A2 (en) | 2017-12-06 | 2020-10-14 | Merck Sharp&Dohme Corp. | Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof |
| KR20210002641A (ko) | 2018-04-30 | 2021-01-08 | 머크 샤프 앤드 돔 코포레이션 | 디메틸술폭시드 중의 동결건조된 돌연변이체 디프테리아 독소의 균질 용액을 제공하는 방법 |
| WO2019212846A1 (en) | 2018-04-30 | 2019-11-07 | Merck Sharp & Dohme Corp. | Methods for producing streptococcus pneumoniae capsular polysaccharide carrier protein conjugates |
| AU2019299836A1 (en) | 2018-07-04 | 2021-02-25 | Vaxcyte, Inc. | Improvements in immunogenic conjugates |
| WO2020010016A1 (en) | 2018-07-04 | 2020-01-09 | Sutrovax, Inc. | Self-adjuvanted immunogenic conjugates |
| JP2022512345A (ja) | 2018-12-12 | 2022-02-03 | ファイザー・インク | 免疫原性多重ヘテロ抗原多糖－タンパク質コンジュゲートおよびその使用 |
| CR20210333A (es) | 2018-12-19 | 2021-08-18 | Merck Sharp & Dohme | Composiciones que comprenden conjugados de polisacárido de streptococcus pneumoniae con proteína y sus métodos de uso |
| JP2022528158A (ja) | 2019-04-10 | 2022-06-08 | ファイザー・インク | コンジュゲート化莢膜糖抗原を含む免疫原性組成物、それを含むキットおよびその使用 |
| EP4003410A1 (en) | 2019-07-31 | 2022-06-01 | Sanofi Pasteur, Inc. | Multivalent pneumococcal polysaccharide-protein conjugate compositions and methods of using the same |
| US20210070890A1 (en) * | 2019-09-06 | 2021-03-11 | Serum Institute Of India Private Limited | Method for obtaining purified bacterial polysaccharides |
| CA3192786A1 (en) | 2020-08-26 | 2022-03-03 | Pfizer Inc. | Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof |
| EP4232593A1 (en) * | 2020-10-22 | 2023-08-30 | Pfizer Inc. | Methods for purifying bacterial polysaccharides |
| KR20230097160A (ko) | 2020-11-04 | 2023-06-30 | 화이자 인코포레이티드 | 폐렴구균 백신에 사용하기 위한 면역원성 조성물 |
| JP2023549736A (ja) | 2020-11-10 | 2023-11-29 | ファイザー・インク | コンジュゲートさせた莢膜糖抗原を含む免疫原性組成物およびその使用 |
| WO2022234416A1 (en) | 2021-05-03 | 2022-11-10 | Pfizer Inc. | Vaccination against pneumoccocal and covid-19 infections |
| JP2024517780A (ja) | 2021-05-03 | 2024-04-23 | ファイザー・インク | 細菌およびベータコロナウイルス感染症に対するワクチン接種 |
| TW202306969A (zh) | 2021-05-28 | 2023-02-16 | 美商輝瑞大藥廠 | 包含結合之莢膜醣抗原的免疫原組合物及其用途 |
| PE20240090A1 (es) | 2021-05-28 | 2024-01-16 | Pfizer | Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados y sus usos |
| WO2023135515A1 (en) | 2022-01-13 | 2023-07-20 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| WO2024084397A1 (en) | 2022-10-19 | 2024-04-25 | Pfizer Inc. | Vaccination against pneumoccocal and covid-19 infections |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4413057A (en) * | 1980-04-14 | 1983-11-01 | Merck & Co., Inc. | Group B streptococcal capsular polysaccharides |
| CA2059692C (en) * | 1991-01-28 | 2004-11-16 | Peter J. Kniskern | Pneumoccoccal polysaccharide conjugate vaccine |
| CA2365296A1 (en) * | 1999-03-19 | 2000-09-28 | Pierre Michel Desmons | Vaccine |
| BRPI0109293B8 (pt) * | 2000-03-16 | 2021-05-25 | Childrens Hospital Philadelphia | métodos para produzir polissacarídeo capsular a partir de um pneumococo, para produzir uma preparação imunogênica para a administração a um animal em risco de desenvolver uma infecção pneumocócica, e para produzir polissacarídeo pneumocócico |
| GB0115176D0 (en) * | 2001-06-20 | 2001-08-15 | Chiron Spa | Capular polysaccharide solubilisation and combination vaccines |
| US20050220777A1 (en) * | 2003-11-21 | 2005-10-06 | Stefan Roos | Selection of lactic acid bacteria enhancing the immune response against Streptococcus pneumoniae |
| PL1866342T3 (pl) | 2005-04-08 | 2019-04-30 | Wyeth Llc | Oddzielanie zanieczyszczeń od polisacharydu Streptococcus pneumoniae przez manipulację pH |
| JP5286089B2 (ja) * | 2006-01-13 | 2013-09-11 | バクスター・インターナショナル・インコーポレイテッド | ポリサッカライドを精製する方法 |
-
2007
- 2007-10-09 MX MX2009003730A patent/MX2009003730A/es active IP Right Grant
- 2007-10-09 JP JP2009532526A patent/JP5260531B2/ja active Active
- 2007-10-09 AU AU2007307800A patent/AU2007307800C1/en active Active
- 2007-10-09 WO PCT/US2007/080768 patent/WO2008045852A2/en active Application Filing
- 2007-10-09 KR KR1020097009585A patent/KR101467002B1/ko active IP Right Grant
- 2007-10-09 CN CN2007800378009A patent/CN101522906B/zh active Active
- 2007-10-09 BR BR122019021950A patent/BR122019021950B8/pt active IP Right Grant
- 2007-10-09 CL CL200702909A patent/CL2007002909A1/es unknown
- 2007-10-09 AT AT07843999T patent/ATE473289T1/de active
- 2007-10-09 US US11/869,206 patent/US7659090B2/en active Active
- 2007-10-09 DE DE602007007642T patent/DE602007007642D1/de active Active
- 2007-10-09 PT PT07843999T patent/PT2074221E/pt unknown
- 2007-10-09 CN CN201210083999.1A patent/CN102648979B/zh active Active
- 2007-10-09 CA CA2665169A patent/CA2665169C/en active Active
- 2007-10-09 DK DK07843999.9T patent/DK2074221T3/da active
- 2007-10-09 ES ES07843999T patent/ES2346929T3/es active Active
- 2007-10-09 BR BRPI0717834A patent/BRPI0717834B8/pt active IP Right Grant
- 2007-10-09 RU RU2009112453/10A patent/RU2460539C2/ru active
-
2009
- 2009-03-24 IL IL197782A patent/IL197782A/en active IP Right Grant
- 2009-04-09 ZA ZA200902502A patent/ZA200902502B/xx unknown
-
2013
- 2013-02-18 HK HK13102016.1A patent/HK1174836A1/xx unknown
-
2014
- 2014-07-31 IL IL233893A patent/IL233893A/en active IP Right Grant
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL233893A0 (en) | Purification of polysaccharides of streptococcus pneumoniae type 3 | |
| UA99278C2 (ru) | Способ получения существенно очищенных капсульных полисахаридов из лизата клеток streptococcus pneumoniae | |
| WO2006087637A3 (en) | Anti her2/neu antibody | |
| WO2007120932A3 (en) | Expression of o-glycosylated therapeutic proteins in prokaryotic microorganisms | |
| ATE537188T1 (de) | Serumalbuminbindende proteine | |
| EA201070987A1 (ru) | Очищенные гибридные белки иммуноглобулина и способы их очищения | |
| WO2010017103A3 (en) | Fully human anti-human nkg2d monoclonal antibodies | |
| WO2006110352A3 (en) | Separation of contaminants from streptococcus pneumoniae polysaccharide by ph manipulation | |
| WO2012009544A3 (en) | Domain insertion immunoglobulin | |
| WO2008023247A3 (en) | Matrix attachment regions (mars) for increasing transcription and uses thereof | |
| PH12015501705A1 (en) | Methods for producing diketopiperazines and compositions containing diketopiperazines | |
| WO2008085962A3 (en) | Cell culture methods for producing recombinant proteins in the presence of reduced levels of one or more contaminants | |
| EP1963506A4 (en) | COMPOSITIONS AND METHODS FOR INCREASING THE PRODUCTION OF RECOMBINANT GAMMA-CARBOXYLATED PROTEINS | |
| WO2008033556A3 (en) | High pressure treatment of proteins for reduced immunogenicity | |
| WO2009043922A3 (en) | Extracellular targets for alzheimer's disease | |
| WO2008039838A3 (en) | Synthetic streptococcus pneumoniae vaccine | |
| MY148837A (en) | Hydrolysed egg proteins | |
| IL218442A0 (en) | Novel antigens and antibodies associated to pancreatic ductal adenocarcinoma | |
| WO2021076574A3 (en) | Fn3 domain-sirna conjugates and uses thereof | |
| WO2005021575A3 (en) | Bacterial signaling molecules that down-regulate pathogenic bacterial virulence properties | |
| Zhao et al. | Deamidization and double enzyme synergetic hydrolysis increasing hydrolysis effeciency of wheat gluten | |
| CN104774822A (zh) | 幽门螺旋杆菌丝氨酸蛋白酶的制备方法 | |
| TW200745337A (en) | Modified process | |
| Mohamad Sait | Determination of stem bromelain activity from pineapple plant (ananas comosus) | |
| Sripuan | Purification, characterization and application of-Galactosidase from Ling-zhi mushroom (Ganoderma lucidum) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration | ||
| HH | Correction or change in general |